Planned Parenthood Exclusion Cuts Contraceptive Provision

This article originally appeared here.
Share this content:
Planned Parenthood Exclusion Cuts Contraceptive Provision
Planned Parenthood Exclusion Cuts Contraceptive Provision

FRIDAY, Feb. 5, 2016 (HealthDay News) -- Exclusion of the Planned Parenthood affiliates in Texas is associated with a reduction in the provision of contraception, according to a study published online Feb. 3 in the New England Journal of Medicine.

Amanda J. Stevenson, from the University of Texas at Austin, and colleagues examined the impact of Planned Parenthood exclusion in Texas, effective Jan. 1, 2013. Data were included for all program claims from 2011 through 2014 to assess changes in the number of claims for contraceptives for two years before and after the exclusion.

The researchers observed relative reductions of 35.5 percent for long-acting reversible contraceptives and of 31.1 percent for injectable contraceptives (both P < 0.001) after the Planned Parenthood exclusion. During this period there was no significant change in the number of claims for short-acting hormonal contraceptive methods. For injectable contraceptives there was a decrease in the percentage of women who returned for a subsequent on-time contraceptive injection among those whose injections were due before versus after the exclusion (56.9 to 37.7 percent) for women in counties with Planned Parenthood affiliates. There was an increase in rate of childbirth covered by Medicaid in counties with Planned Parenthood affiliates within 18 months after the claim.

"The exclusion of Planned Parenthood affiliates from a state-funded replacement for a Medicaid fee-for-service program in Texas was associated with adverse changes in the provision of contraception," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »